The Delhi High Court in Intra Cellular Therapies v. Controller of Patents addressed pivotal issues in pharmaceutical patent law concerning disclosure in genus-species claims and therapeutic efficacy under Section 3(d). The ruling highlights both advancements and shortcomings in the Court's analysis relevant for practitioners in patent law.
Delhi High Court Revisits Pharmaceutical Patent Law in Intra Cellular Therapies Case
The Delhi High Court recently made significant rulings in Intra Cellular Therapies v. Controller of Patents, focusing on key issues of patent law.
This judgment delves into the intricacies of the coverage-disclosure distinction within genus-species claims, and addresses the therapeutic efficacy threshold defined under Section 3(d) of the Patents Act. The Court’s engagement with Section 3(d) was noted for its clarity, yet its treatment of coverage as disclosure and lack of depth regarding the novelty standard raises concerns.
While the ruling attempts to clarify the requirements for therapeutic efficacy, it does not sufficiently address how these requirements align with established standards for patent novelty and inventive step. The absence of a robust engagement with the inventive step criteria could have implications for future patent applications in the pharmaceutical domain.
This decision is crucial for practitioners engaged in pharmaceutical patent law as it sheds light on the evolving interpretations of efficacy and novelty, urging a greater emphasis on these criteria in future applications.
Citations
- Intra Cellular Therapies v. Controller of Patents (2026) Delhi High Court
